A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)
Phase 1
Not yet recruiting
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002952
- Lead Sponsor
- The First Hospital of He'nan University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. patients with 2019-nCoV pneumonia;
2. Sign informed consent.
Exclusion Criteria
1. Patients complicated with active tuberculosis, malignant arrhythmia, acute myocardial infarction and stroke;
2. pregnant and lactating women;
3. Patients complicated with severe cognitive and mental disorders;
4. Clinical investigators who are participating in other interventions within one month prior to enrollment;
5. Those who are known to be allergic to therapeutic drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of integrated traditional Chinese and western medicine in treating SARS-CoV-2 viral replication and immune response modulation?
How does the combination of traditional Chinese medicine and western medicine compare to standard-of-care treatments in reducing viral load and improving clinical outcomes for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection?
What biomarkers are associated with patient selection and response prediction in integrated traditional Chinese and western medicine treatment for SARS-CoV-2-induced pneumonia?
What are the known or potential adverse events associated with the use of integrated traditional Chinese and western medicine in the management of SARS-CoV-2 pneumonia, and what are the recommended management strategies?
What related compounds or combination approaches are being explored in conjunction with traditional Chinese medicine for the treatment of SARS-CoV-2-induced pneumonia, and how do they compare to other competitor drugs in the therapeutic landscape?